- See the difference! Customize Seeking Alpha: Sign in or join
Seeking Alpha
-
Friday, September 3rd
Cadus: Buying a Dollar for 50 Cents, Literally
-
A Look at Immunogen Beyond the T-DM1 Setback
-
Arena Pharma: Understanding the Market for Anti-Obesity Drugs
-
Future of Genzyme / Isis Pharma's Cholesterol Drug Still Up in the Air
-
Pfizer Acts on Growing Interest in Niche Drugs
-
Thursday, September 2nd
Martek Biosciences Beats Estimates on Surging Sales
-
Preparing for Inspire Pharmaceutical's 2011 Phase 3 Catalyst
-
Wednesday, September 1st
Good News for Alimera’s Pipeline
-
Immunogen: What Really Happened With T-DM1’s Filing?
-
BioMarin Pipeline Update
-
Will Roche Job Cuts Include China Positions?
-
The Fight for Market Share in Blood Thinners Is On
-
Tuesday, August 31st
Sanofi Still Bidding for Genzyme - And at the Same Price
-
Monday, August 30th
FDA Committee Rejects Expanded Use of Jazz Drug on Abuse Concerns: Biotech's Latest Failures
-
Roche Dominates the Biotech Deal Flow
-
Vascular Solutions Is One of the Industry's Attractive Takeover Targets
-
Cypress Risks Deepening Disquiet With Another Spending Spree
-
Sunday, August 29th
Big Pharma: Why In-Licensing Is Not the Cure
-
Why I Bought ImmunoGen After the Plunge
-
Friday, August 27th
Ziopharm Oncology: Place Your Bets
-
Arena Pharma: Using Options to Trade on FDA's Decision for Key Obesity Drug
-
Sanofi-Aventis and Genzyme: Walking Away?
-
Diabetes Drugs From Takeda, GSK Found to Pose Similar Risks
-
Interview: Cleveland BioLabs CEO Discusses Recent Developments, Milestones Ahead
-
Roche Bets Big on Peptides for Tackling Tough Diseases